# BEAM — slm-full-cpu

## Metadata

ticker: BEAM
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 1beaaaa3260cf6ba7ee24e3a3cd9fbf94f546202c75347fe298db0432c0f17ae
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 739, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 169.275, "latency_s_total": 169.275, "parse_failure": 0, "prompt_tokens": 3093, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 451, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 135.29, "latency_s_total": 135.29, "parse_failure": 0, "prompt_tokens": 2340, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 132, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 42.699, "latency_s_total": 42.699, "parse_failure": 0, "prompt_tokens": 699, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 152, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 51.302, "latency_s_total": 51.302, "parse_failure": 0, "prompt_tokens": 693, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 164, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 58.82, "latency_s_total": 58.82, "parse_failure": 0, "prompt_tokens": 523, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 134, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 65.266, "latency_s_total": 65.266, "parse_failure": 0, "prompt_tokens": 819, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 903, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 146.537, "latency_s_total": 146.537, "parse_failure": 0, "prompt_tokens": 1542, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 25.22,
  "currency": "USD",
  "market_cap": 2604914688.0,
  "forward_pe": -5.3191376,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "financial_currency": "USD",
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin_pct": -55.45,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the Annual Report on Form 10-K for ticker BEAM, here are the key takeaways regarding the company's financial position, risks, and operational status:

**Financial Performance and Losses**
*   **Significant Operating Losses:** The company has incurred substantial losses since inception, with net losses of $80.0 million (2025), $376.7 million (2024), and $132.5 million (2023). As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Path to Profitability:** The company expects to incur losses for the foreseeable future and may never achieve profitability. It has not yet completed any pivotal clinical trials or obtained marketing approval for any product candidates.
*   **Cash Position:** As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities. Management believes this amount is sufficient to fund operating expenses and capital expenditures for at least the next 12 months, though this could change due to unknown factors.

**Capital Requirements and Funding Risks**
*   **Need for Additional Funding:** The company will require substantial additional capital to continue research and development, expand clinical trials, seek marketing approvals, and potentially commercialize products.
*   **No Committed Capital Sources:** Aside from a credit facility with Sixth Street Lending Partners, the company has no committed external source of additional capital.
*   **Consequences of Funding Shortfalls:** If the company cannot raise capital on acceptable terms or in sufficient amounts, it may be forced to delay, reduce, or eliminate research programs, curtail commercialization efforts, or terminate license and collaboration agreements.
*   **Past Restructuring:** In October 2023, the company announced a portfolio repriorization and strategic restructuring, which included pausing or eliminating certain pipeline programs to reduce expenses.
*   **Dilution and Restrictions:** Raising additional capital through equity or convertible debt will dilute existing stockholders. Debt financing, such as the agreement with Sixth Street Lending Partners, includes covenants that restrict actions like incurring additional debt, making capital expenditures, or declaring dividends.

**Operational Status and History**
*   **Early-Stage Company:** Founded in January 2017 and beginning operations in July 2017, the company has a short operating history. Most product development programs are in early clinical, preclinical, or research stages, carrying a high risk of failure.
*   **Lack of Commercial Track Record:** The company has not demonstrated the ability to complete pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale medicines, or conduct sales and marketing activities for commercialization.
*   **Expense Drivers:** Operating expenses are expected to increase significantly due to costs associated with advancing clinical trials, maintaining intellectual property, hiring personnel, developing the base editing platform, and potentially establishing sales and distribution infrastructure.

**Strategic Uncertainties**
*   **Unpredictable Outcomes:** Due to the numerous risks associated with developing base editing product candidates, the company cannot predict the extent of future losses or when, if ever, it will become profitable.
*   **Collaboration Dependencies:** The company relies on collaborations and license agreements. Failure to meet payment obligations under these agreements could lead to termination. Additionally, seeking collaborators may force the company to relinquish rights to its technologies or product candidates on unfavorable terms.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Capital:** The company has incurred significant operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to continue incurring significant expenses and operating losses for the foreseeable future and may never achieve profitability.
*   **Need for Additional Funding:** Substantial additional funding is required to support continuing operations, including research and development, clinical trials, and potential commercialization. If capital cannot be raised when needed or on attractive terms, the company may be forced to delay, reduce, or eliminate research programs or commercialization efforts. There is no committed source of additional capital other than a credit facility with Sixth Street Lending Partners.
*   **Lack of Commercialization Experience:** The company has not yet demonstrated the ability to successfully complete pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale medicines, or conduct the sales and marketing activities necessary for successful commercialization.
*   **Limited Operating History:** The company has a short operating history in the rapidly evolving base editing and gene editing fields, making it difficult to evaluate the technology, industry, and future performance. This limited history subjects assessments of future success to significant uncertainty.
*   **Development and Regulatory Risks:** Developing product candidates is time-consuming, expensive, and uncertain. The company has not completed any pivotal clinical trials and may never have a product candidate approved for commercialization. Even if products are approved, they may not achieve commercial success.
*   **Operational and Strategic Risks:** The company may encounter unforeseen expenses, difficulties, and delays. Past actions, such as the portfolio reprioritization and strategic restructuring announced in October 2023, have resulted in the pausing or elimination of certain pipeline programs. Additionally, license and collaboration agreements may be terminated if the company fails to meet payment or other obligations.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc. (BEAM) currently trades at $25.22 with a market capitalization of approximately $2.6 billion. The company reported revenue of $156.0 million, but continues to operate with a negative net income of $86.5 million, resulting in a profit margin of -55.45%. Consequently, the forward P/E ratio is negative, reflecting ongoing losses rather than profitability. This financial profile indicates a high-risk, pre-profitability stage typical of biotechnology firms heavily invested in R&D. Investors should note that the company does not currently pay a dividend.

### Recent Developments

Beam Therapeutics Inc. (BEAM) is currently trading at $25.22, reflecting a market capitalization of approximately $2.6 billion despite a negative profit margin of -55.45% and a forward P/E ratio indicating ongoing losses. The company recently filed its 10-K annual report on February 24, 2026, and is scheduled to submit its 10-Q quarterly report on August 4, 2026, both of which highlight significant risk factors that could materially impact financial results. Investors should closely monitor these regulatory filings for updates on operational challenges and cash burn rates, as the biotechnology sector remains highly sensitive to clinical and financial uncertainties.

### SEC Filing Highlights
Beam Therapeutics reported a net loss of $80.0 million for 2025, bringing its accumulated deficit to $1.6 billion as it continues to incur substantial operating losses. The company holds $1.2 billion in cash and marketable securities, which management believes is sufficient to fund operations for at least the next 12 months. However, Beam has no committed external capital sources beyond a credit facility and warns that it may never achieve profitability. Consequently, the company faces significant risks related to funding shortfalls, potential dilution, and the need to raise additional capital to sustain its early-stage clinical programs.

### Risk Factors

*   **Financial Viability and Capital Requirements:** The company has a history of significant operating losses and a substantial accumulated deficit, requiring additional funding to sustain operations; failure to secure capital on attractive terms could force the delay or termination of research and commercialization efforts.
*   **Regulatory and Commercialization Uncertainty:** BEAM lacks a track record of completing pivotal clinical trials or obtaining marketing approvals, and faces significant risks related to manufacturing, sales, and marketing capabilities, meaning product candidates may never achieve commercial success.
*   **Limited Operating History and Strategic Execution:** As a company with a short history in the rapidly evolving gene editing field, future performance is subject to high uncertainty, compounded by past strategic restructuring that paused or eliminated pipeline programs and potential risks from the termination of key collaboration agreements.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. (BEAM) is a gene-editing company operating in a high-risk, pre-profitability stage with a market capitalization of approximately $2.6 billion and reported revenue of $156.0 million. The stock is notable for its substantial cash reserves of $1.2 billion, which provide a runway to fund operations for at least the next 12 months despite an accumulated deficit of $1.6 billion and ongoing negative net income. The single most important near-term variable is the company’s ability to secure additional external capital or achieve clinical milestones without triggering significant dilution or program termination.

### Outlook
The directional outlook for Beam Therapeutics is cautiously constructive, supported by a robust balance sheet that mitigates immediate solvency concerns, but remains heavily weighted toward binary clinical and regulatory outcomes. Key variables to monitor include the progress of early-stage clinical programs, the execution of strategic partnerships, and the company’s capacity to manage cash burn while navigating the lack of committed external capital sources. The thesis would strengthen if Beam demonstrates clear pathways to commercialization or secures favorable financing terms that extend its runway without excessive dilution; conversely, the view would weaken if clinical setbacks occur or if the company is forced to raise capital under unfavorable market conditions, given the inherent uncertainty of its limited operating history and the absence of a proven track record in bringing gene-editing therapies to market.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

## EXECUTIVE SUMMARY

---

CLAIM: "market capitalization of approximately $2.6 billion"
LABEL: SUPPORTED
REASON: The raw source data lists market_cap as $2,604,914,688.0, which rounds to approximately $2.6 billion, consistent with the pre-written Financial Health section.

---

CLAIM: "reported revenue of $156.0 million"
LABEL: SUPPORTED
REASON: The raw source data lists revenue as $156,035,008.0, which rounds to $156.0 million, as also stated in the pre-written Financial Health section.

---

CLAIM: "cash reserves of $1.2 billion"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and SEC Filing Highlights pre-written section both explicitly state the company held $1.2 billion in cash, cash equivalents, and marketable securities as of December 31, 2025.

---

CLAIM: "provide a runway to fund operations for at least the next 12 months"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "Management believes this amount is sufficient to fund operating expenses and capital expenditures for at least the next 12 months," and this is echoed in the pre-written SEC Filing Highlights section.

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: Both the RAG — SEC Highlights and RAG — Risk Factors explicitly state "As of December 31, 2025, the accumulated deficit stood at $1.6 billion," also confirmed in the pre-written SEC Filing Highlights section.

---

CLAIM: "ongoing negative net income"
LABEL: SUPPORTED
REASON: The raw source data shows net_income of -$86,520,000, and the RAG sections confirm net losses of $80.0 million for 2025 (10-K figure) and ongoing operating losses; negative net income is directly supported.

---

CLAIM: "the company's ability to secure additional external capital or achieve clinical milestones without triggering significant dilution or program termination"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and Risk Factors pre-written section both explicitly discuss the risk of dilution from equity raises and the potential need to delay or terminate programs if capital cannot be secured; no specific quantitative figure is embedded here, but the qualitative framing is directly grounded in the source.

---

## OUTLOOK

---

CLAIM: "robust balance sheet that mitigates immediate solvency concerns"
LABEL: INFERENCE
REASON: This is a directional characterization derivable from the explicitly stated $1.2 billion cash position and the 12-month runway statement in the source data, making it a reasonable inference from those two present facts without requiring any absent data.

---

CLAIM: "lack of committed external capital sources"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states "the company has no committed external source of additional capital" beyond the Sixth Street credit facility, and this is echoed in the pre-written SEC Filing Highlights and Risk Factors sections.

---

CLAIM: "limited operating history"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights and Risk Factors both explicitly reference the company's "short operating history," founded January 2017 and beginning operations July 2017.

---

CLAIM: "absence of a proven track record in bringing gene-editing therapies to market"
LABEL: SUPPORTED
REASON: The RAG — SEC Highlights explicitly states the company "has not demonstrated the ability to complete pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale medicines, or conduct sales and marketing activities for commercialization," directly supporting this characterization.

---

### Summary of Additional Checks

**No specific price targets, explicit percentage thresholds, named product milestones, or forward-looking numerical figures** (beyond those already evaluated above) appear in the Executive Summary or Outlook sections. The 52-week high ($38.26) and 52-week low ($20.23) present in the raw data are **not cited** in these sections, so no positional arithmetic check is triggered. The profit margin figure (-55.45%) and forward P/E (-5.32) present in the source data are also **not cited** in the Executive Summary or Outlook (they appear only in the pre-written Financial Health/Recent Developments sections), so no additional entries are required.
